Symptom burden and survival outcome: 3 cycles versus 6 cycles of chemotherapy in advanced NSCLC

Autor:	Tito R. Mendoza, Charles Lu, Q. Shi, Charles S. Cleeland, D. Fariclough, Gary M. Mobley, L. Palos, X. S. Wang
Rok vydání:	2007
Předmět:	Oncology Cancer Research medicine.medical_specialty Chemotherapy business.industry Optimal treatment medicine.medical_treatment Symptom burden Palliative chemotherapy Survival outcome Surgery Quality of life Internal medicine medicine Primary treatment business
Zdroj:	Journal of Clinical Oncology. 25:17054-17054
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2007.25.18_suppl.17054
Popis:	17054 Background: Improving survival and quality of life is the primary treatment goal for patient with advanced NSCLC receiving palliative chemotherapy. The optimal treatment duration remains to be determined, and there are few studies that examine longitudinal symptom burden in this population. Methods: We prospectively collected self-reported symptom data from advanced stage NSCLC patients receiving chemotherapy. Symptom data was collected weekly utilizing the MD Anderson Symptom Inventory (15 symptoms) pre chemotherapy until therapy discontinuation or up to 26 weeks. Principal components analysis of symptoms measures with a Varimax rotation were used to identify symptom clusters. A piecewise linear mixed-effect regression model was used to estimate the changes over time in symptom severity, and Cox modeling was used for data analysis. Results: Data from 102 subjects were available for analysis. Chemotherapy was primarily discontinued because of tumor progression or a decline in the patient's functional status. Seventy patients received only 2 cycles of chemotherapy, while 46 and 29 patients received 4 and 6 cycles of chemotherapy, respectively. Four clusters of symptoms were identified prior to therapy, including: general symptoms (such as pain, fatigue, sleeping disturbance), GI distress (nausea, vomiting, lack of appetite & constipation), affective symptoms (sadness & distress) and specific disease related symptoms (coughing & shortness of breath). In patients who received = 3 cycles of chemotherapy, a rapid increased in symptom severity was observed, compared to those who received > 3 cycles (P 3 of chemotherapy (HR=9.9, CI=4–22.7, P No significant financial relationships to disclose.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1e48dfe261c61e408c5a8392a785a3bf https://doi.org/10.1200/jco.2007.25.18_suppl.17054 Zobrazit plný text záznamu